Navigation Links
Seattle's Swedish Cancer Institute First in U.S. to Treat Cancer Patient with Elekta VMAT
Date:7/30/2008

l enable us to design treatment approaches that are more aggressive in killing cancer cells and have fewer side effects."

Dr. Mehta says the implementation of Elekta VMAT at Swedish Cancer Institute has advanced the program's overall mission. "By introducing VMAT technology today, we have continued to build on the Swedish Cancer Institute's rich tradition of innovation in cancer care. We were among the first to begin using Image Guided Radiation Therapy (IGRT) utilizing cone Beam CT technology to improve setup accuracy and treatment precision, and now we've begun treating with VMAT. As the largest and most comprehensive cancer treatment program in the Pacific Northwest, improving patient care is our mission and we work daily to make that a reality."

About Elekta VMAT

The speed and precision of Elekta VMAT is made possible by the simultaneous manipulation of the gantry position and speed, the multileaf collimator leaves, the dose rate and the collimator angle, all while the radiation beam is on. In addition, Elekta VMAT allows the flexibility of one arc, two arcs, sub-arc or a combination.

To ensure the accuracy of this highly conformal treatment, Elekta VMAT uses daily ultra low dose 3D volumetric imaging via Elekta VolumeView(TM). VolumeView imaging is accomplished in under two minutes, complementing the speed of treatments. For additional information, visit http://www.elekta.com/vmat .

About Elekta

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state-of-the-art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and information systems, as well as services for improved cancer care and management of brain disorders.

Elekta's systems and solutions are used in over 5,000 hospitals around the world. Clinica
'/>"/>

SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
2. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
3. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
4. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
5. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
6. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
7. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
8. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
9. New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer
10. Nemours Center for Childhood Cancer Research Team at the Alfred I. duPont Hospital for Children Identifies the Function of a Biomarker Present in Prostate Cancer Cells: New Insight into Therapeutic Benefit for Patients with Advanced Prostate Cancer
11. BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Taskforce representing Canada,s living victims of ... the Minister and Health Canada have put into this program ... of the thalidomide survivors, and more than 70% of them ... annual adjustments for inflation. Certain of the thalidomide ... on the severity of their disability, tax free, with inflation ...
(Date:5/22/2015)... HILL, N.C. , May 22, 2015 /PRNewswire/ ... critical to pharmaceutical brand recognition and success. ... LLC conducted a study to provide pharmaceutical and ... of investment (FTEs and budget) that are being ... Pharmaceutical and biotech marketing managers can utilize this ...
(Date:5/22/2015)... , May 22, 2015 The leading ... $13 billion global cardiac rhythm management device market ... found that Medtronic, St. Jude Medical, Boston Scientific ... of this market segment. The healthcare market research ... , uses 2015 as a base year, providing ...
Breaking Medicine Technology:Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... A live auction will be held to sell over ... other medical facilities around the United States. Various types ... anesthesia, exam and much more. , The live auction ... starting at 9:00am CDT each day. The equipment is at ... Park, IL 60160. Anyone can participate in the auction ...
(Date:5/22/2015)... The world is at a ... intersecting to create new opportunities for leadership in ... at WesternU's 34th annual Commencement Exercises said Wednesday, ... a former San Francisco mayor and likely 2018 ... graduation ceremony for WesternU's colleges of Allied Health ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
... , SUNDAY, May 13 (HealthDay News) -- A new type ... people who have lost their vision due to degenerative eye ... research with rats. The system uses tiny solar panel-like ... a specially designed pair of goggles equipped with a miniature ...
... new study has found that, contrary to current thinking, taking ... a person,s risk of developing colorectal cancer. Published early online ... Cancer Society, the study also revealed that even long-term use ... cancer risk. In recent years, researchers have thought that ...
... , THURSDAY, May 10 (HealthDay News) -- An advisory panel ... approval of the weight-loss medication lorcaserin, even though concerns remain ... give the nod to the drug, lorcaserin would become the ... decade. The FDA is not bound to follow the advice ...
... is the leading cause of death among children under 5, ... Johns Hopkins Bloomberg School of Public Health. They examined the ... found that 64 percent were attributable to infectious causes and ... the May issue of the Lancet , suggest a ...
... who are making a big difference in the highly ... two early-stage discovery awards from Grand Challenges Explorations, an ... The global health projects will focus on creating ... for low-cost, in-home diagnoses. The prestigious awards ...
... reduced mobility now have access to specialized exercise equipment ... between the University of Alberta and the Spinal Cord ... functional electrical stimulation (FES) rehabilitation therapy machines are now ... the Faculty of Physical Education and Recreation at the ...
Cached Medicine News:Health News:In Rat Study, Eye Device Shows Promise for Restoring Sight 2Health News:Blood pressure drugs don't protect against colorectal cancer 2Health News:FDA Panel Gives Blessing to New Weight-Loss Drug 2Health News:Pneumonia and preterm birth complications are the leading causes of childhood death 2Health News:2 Grand Challenges Explorations grants for global health 2Health News:Partnership provides inclusive workout 2Health News:Partnership provides inclusive workout 3
... The assay is a direct competitive ... in human serum or plasma. A specific ... it available for antibody binding. Estradiol then ... to fluorescein isothiocyanate (FITC) and alkaline phosphatase ...
... the most potent, naturally secreted estrogen and ... ovary [1]. In the ovary, estradiol is ... a less potent estrogen derived from androstenedione. ... body tissues. In men, small amounts of ...
... troponin I (cTnI) has been useful in ... Emergency Departments (ED) with chest pain. 18-20 ... when blood levels of sensitive and specific ... isoenzyme of creatine kinase (CK-MB), and myoglobin, ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
Medicine Products: